Galectin-3 Identifies a Subset of Macrophages With a Potential Beneficial Role in Atherosclerosis
Overview
Authors
Affiliations
Objective: Galectin-3 (formerly known as Mac-2), encoded by the gene, is proposed to regulate macrophage adhesion, chemotaxis, and apoptosis. We investigated the role of galectin-3 in determining the inflammatory profile of macrophages and composition of atherosclerotic plaques. Approach and Results: We observed increased accumulation of galectin-3-negative macrophages within advanced human, rabbit, and mouse plaques compared with early lesions. Interestingly, statin treatment reduced galectin-3-negative macrophage accrual in advanced plaques within hypercholesterolemic (apolipoprotein E deficient) mice. Accordingly, compared with : mice, : mice displayed altered plaque composition through increased macrophage:smooth muscle cell ratio, reduced collagen content, and increased necrotic core area, characteristics of advanced plaques in humans. Additionally, macrophages from mice exhibited increased invasive capacity in vitro and in vivo. Furthermore, loss of galectin-3 in vitro and in vivo was associated with increased expression of proinflammatory genes including MMP (matrix metalloproteinase)-12, CCL2 (chemokine [C-C motif] ligand 2), PTGS2 (prostaglandin-endoperoxide synthase 2), and IL (interleukin)-6, alongside reduced TGF (transforming growth factor)-β1 expression and consequent SMAD signaling. Moreover, we found that MMP12 cleaves macrophage cell-surface galectin-3 resulting in the appearance of a 22-kDa fragment, whereas plasma levels of galectin-3 were reduced in : mice, highlighting a novel mechanism where MMP12-dependent cleavage of galectin-3 promotes proinflammatory macrophage polarization. Moreover, galectin-3-positive macrophages were more abundant within plaques of : mice compared with : animals.
Conclusions: This study reveals a prominent protective role for galectin-3 in regulating macrophage polarization and invasive capacity and, therefore, delaying plaque progression.
Immune checkpoint landscape of human atherosclerosis and influence of cardiometabolic factors.
Barcia Duran J, Das D, Gildea M, Amadori L, Gourvest M, Kaur R Nat Cardiovasc Res. 2024; 3(12):1482-1502.
PMID: 39613875 PMC: 11634783. DOI: 10.1038/s44161-024-00563-4.
Limited Alleviation of Lysosomal Acid Lipase Deficiency by Deletion of Matrix Metalloproteinase 12.
Buerger M, Amor M, Akhmetshina A, Bianco V, Perfler B, Zebisch A Int J Mol Sci. 2024; 25(20).
PMID: 39456786 PMC: 11506919. DOI: 10.3390/ijms252011001.
Lysosomes in the immunometabolic reprogramming of immune cells in atherosclerosis.
Bonacina F, Zhang X, Manel N, Yvan-Charvet L, Razani B, Norata G Nat Rev Cardiol. 2024; 22(3):149-164.
PMID: 39304748 PMC: 11835540. DOI: 10.1038/s41569-024-01072-4.
Du S, Chen J, Kim H, Lichtenstein A, Yu B, Appel L J Nutr. 2024; 154(11):3235-3245.
PMID: 39299474 PMC: 11600079. DOI: 10.1016/j.tjnut.2024.08.029.
Protective innate immunity against does not require Stat6-dependent macrophage polarization.
Mousso T, Pollock S, Inzerillo P, Gigliotti F, Wright T Infect Immun. 2024; 92(10):e0022224.
PMID: 39150267 PMC: 11475768. DOI: 10.1128/iai.00222-24.